Company intelligence / Profile preview

Merz Australia

North Ryde, New South Wales, Australia

Ownership: Private
Employees: ~50
Development stage: Other

Overview

Merz Australia is the regional subsidiary of the global Merz Pharma Group, specializing in medical aesthetics and neurotoxin therapy. The company provides a comprehensive portfolio of products including the botulinum toxin Xeomin, the Belotero and Radiesse filler ranges, and the Ultherapy skin lifting system. Merz Australia operates through two main pillars: Merz Aesthetics, which focuses on self-care and aesthetic medicine, and Merz Therapeutics, which addresses movement disorders and neurological conditions. The company is committed to providing innovative treatments that improve patient health and confidence across the Australian and New Zealand markets.

Therapeutic areas: NeurologyDermatology
Modalities: BiologicDeviceSmall moleculeProtein
Industry: Pharma

Beyond the preview

Go deeper on Merz Australia.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Merz Australia.

Explore the full profile